Hosted on MSN14d
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31 with the first subjects now dosed in this ...
Monthly Prescribing Reference3y
Prevnar 20
Pneumococcal 20-valent conjugate vaccine (diphtheria CRM197 protein ... After shipping, Prevnar 20 may arrive at temperatures between 2 ºC to 25 ºC (36 ºF to 77 ºF). Upon receipt, store ...
Monthly Prescribing Reference7y
Pneumovax 23
2 controlled studies in South Africa evaluated ... meningococcal polysaccharide serogroup A or placebo. The 6- and 12-valent vaccines achieved a protective efficacy of 76% and 92%, respectively ...
Nature5y
2 Synflorix™: What Have We Learned From Immunogenicity Studies?
Synflorix™ (10-valent pneumococcal conjugate vaccine; GlaxoSmithKline Biologicals ... following priming was observed between continents. 2,3 In European studies, Synflorix™ was proven to ...
Yahoo Finance15d
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31
Advancement to Stage 2 follows a blinded assessment of ... tolerability and immunogenicity of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal ...
Medscape4y
Observed Differences in Invasive Pneumococcal Disease Epidemiology after Routine Infant Vaccination
Healthy children get a 3 + 0 dose schedule, children at risk do get fourth dose of pneumococcal conjugate vaccine (PCV) at 12 months of age, and a booster dose of 23-valent polysaccharide vaccine ...